Deliver Your News to the World

Bioneb Ltd Announces the Development of a Revolutionary Reduced Risk Product Pulmonary Drug Delivery System for the Nicotine Replacement Therapy Market

New York, NY – WEBWIRE

Bioneb Limited Founder and President, Nick Havercroft, announced today that Bioneb has developed what is perceived to be the world’s most efficient pulmonary drug delivery system for Human Pharmaceutical Grade Medical Nicotine formulation. The pulmonary delivery device uses FDA 510K approved Ultrasonic Atomizing Vibrating Micron Micro Mesh technology.

The device is able to deliver nicotine through the pulmonary tract with +80% efficiency and includes a patent pending disposable cartridge (vial) based on the “K” cup concept filled with the patent pending Nicotine formulation, formulated in such a way as to be free of chemicals and does not require any heating.

Due to the efficiency of the delivery system, nicotine medications in various strengths may be introduced in a single “unit dose” for medical nicotine replacement therapy and may also be used in the reduced risk tobacco product market for pleasure. The nicotine solution may contain less than 1% nicotine extract due to its efficiency. A fine vapor like mist is produced which is inhaled but requires no heating of the formulation to produce the vapor. The formulation contains no chemicals such as propylene glycol and produces no carcinogenics, no smell and no second hand vapor or smoke. The device can be used in all areas where traditional tobacco products and electronic cigarettes are banned.

With the disposable refill cartridge concept, this ensures that there is no need for messy refilling, no chance of overdose, no contamination of the formulation, it’s hygienic and there is less chance of accidents happening with children which has been the case with electronic cigarette juice.

Mr. Havercroft stated: “Although the nicotine drug delivery device is not a electronic cigarette, it complies with all the new legislation required for electronic cigarettes, making it a unique product in the nicotine replacement therapy and reduced risk tobacco product market. The beauty of this device is that in essence, it is a medical device that can be distributed and sold in both the traditional pharmaceutical outlets and also in the traditional tobacco outlets and markets. This a revolutionary device which has many uses in the medical market and is not limited to the nicotine replacement therapy market or the reduced risk product of the tobacco industry.”

Mr. Havercroft stated that he has presented the drug delivery device to and entered into discussions with two of the big four international tobacco companies and signed NDA’s with both companies. Both companies have shown great interest in the product and conducted testing of the device and nicotine formulations with results being very positive. However, discussions have been discontinued as Mr. Havercroft felt the NDA’s were not being honored. Mr. Havercroft is seeking legal advice regarding the actions of one of the two big tobacco companies whom he feels are in breach of the NDA.


 nicotine replacement
 reduced risk product
 pulmonary delivery
 drug delivery device

This news content may be integrated into any legitimate news gathering and publishing effort. Linking is permitted.

News Release Distribution and Press Release Distribution Services Provided by WebWire.